Navigation Links
Common antibiotics and blood pressure medication may result in hospitalization
Date:1/17/2011

Mixing commonly used antibiotics with common blood pressure medications may cause hypotension (abnormally low blood pressure) and induce shock in older patients, requiring hospitalization, according to a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100702.pdf.

"Macrolide antibiotics (erythromycin, clarithromycin and azithromycin) are among the most widely prescribed antibiotics, with millions of prescriptions dispensed in Canada each year." writes Dr. David Juurlink, Scientist at the Sunnybrook Research Institute and the Institute for Clinical Evaluative Sciences with coauthors. "The drugs are generally well-tolerated, but they can cause several important drug interactions."

This study was conducted among Ontarians 66 years and older who were treated with a calcium-channel blocker (drugs often used to treat high blood pressure) between 1994 and 2009. The researchers then identified those who were hospitalized for low blood pressure and, in that group, whether or not a macrolide antibiotic had been prescribed shortly beforehand.

The researchers identified 7100 patients hospitalized for low blood pressure or shock while taking a calcium channel blocker. Treatment with erythromycin was found to increase the risk of low blood pressure almost 6-fold, while clarithromycin increased the risk almost 4-fold. In contrast, azithromycin did not increase the risk of hypotension.

"In older patients receiving calcium channel blockers, the two macrolide antibiotics erythromycin and clarithromycin are associated with a major increase in the risk of hospitalization for hypotension," conclude the authors. "However, the related drug azithromycin appears safe. When clinically appropriate, it should be used preferentially in patients receiving a calcium channel blocker."


'/>"/>

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal
Source:Eurekalert

Page: 1

Related biology news :

1. Study provides insight on a common heart rhythm disorder
2. Researchers identify Achilles heel of common childhood tumor
3. First comprehensive genomic study of common cold reveals new treatment targets
4. GUMC researchers hone in on new strategy to treat common infection
5. Hairspray is linked to common genital birth defect, says study
6. Common food additive found to increase risk and speed spread of lung cancer
7. Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases
8. Scientists uncover evolutionary keys to common birth disorders
9. Common soil mineral degrades the nearly indestructible prion
10. Genetic testing not cost-effective in guiding initial dosing of common blood thinner
11. New vaccine developed for preventing uncommon cold virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... The Scripps Research Institute have found evidence in laboratory ... recognize methamphetamine and boost tolerance to the drug through ... human studies, could help explain why chronic users go ... as speed. The study could lead to new treatments ...
... "dead zone" area of the Gulf of Mexico ?a region ... huge marine life losses ?has appeared much earlier this year, ... marine life more adversely than normal, researchers are reporting. , ... at Galveston, Louisiana State University and NASA recently surveyed the ...
... little follow-up on open access publishing and the ... The final National Institutes of Health (NIH) rule on ... of federal research dollars and a missed opportunity to ... to a group of the nation's leading not-for-profit medical ...
Cached Biology News:Chemists identify immune system mechanism for methamphetamine binges 2Chemists identify immune system mechanism for methamphetamine binges 3Dead zone area in Gulf could be increasing, researchers say 2Not-for-profit publishers call NIH public access rule a missed opportunity 2Not-for-profit publishers call NIH public access rule a missed opportunity 3
(Date:12/19/2014)... , Dec. 18, 2014   ISN has ... Safety Performance Indicators publication series. With data ... activity reported in 2013 within its online contractor management ... safety key performance indicator (KPI) statistics. ... U.S. publication is available in two industry ...
(Date:12/17/2014)... York, NY (PRWEB) December 16, 2014 ... significant changes since 2013, which is why IBISWorld updated ... this industry continues to benefit from an intensified focus ... the proposal for new emission standards for power plants ... industry operators. According to IBISWorld Industry Analyst Sarah Kahn, ...
(Date:12/17/2014)... 2014 “Never say, ‘I cannot ... Marburg’s Department of Physics, advises young women pursuing ... released SPIE Women in Optics 18-month planner ... to ask questions.” , In the annual planner, ... occupations ranging from university professor and laboratory researcher ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... August 28 XTL Biopharmaceuticals,Ltd. (NASDAQ: XTLB ... in the acquisition, development and commercialization of,therapeutics for ... and hepatitis C, today announced that issuances of,American ... bank,The Bank of New York, will be processed ...
... for,Lifesaving Cures revealed today a consequence of the ... by opponents of embryonic stem,cell research: It is ... exclude Missourians with common chromosomal abnormalities like Down,Klinefelter ... In their blind rush to put their ...
... 2 (DRC) announced,today the purchase of 25% of ... for $92.5M. DRC will also provide a $15M,milestone ... be met.,PEG-INTRON (peginterferon alpha-2b), is approved for the ... Schering-Plough Corporation (SGP). Speaking on behalf of ...
Cached Biology Technology:Processing Fees on ADRs to be Waived for two Months 2Processing Fees on ADRs to be Waived for two Months 3New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human 2Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2
... FHS-LVF, and the CVD-Diffuse We've combined ... Filters to create the world's first notch ... adjustable bandpass. Each filter features an excellent ... These filters -- with interference coatings ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Ms anti-Cyclophilin D...
Protein Kinase D2 Immunogen: Human protein kinase D2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: